Apotea AB (publ)
STO:APOTEA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Apotea AB (publ)
STO:APOTEA
|
SE |
|
Lagnam Spintex Ltd
NSE:LAGNAM
|
IN |
|
Oracle Corp Japan
TSE:4716
|
JP |
|
Carisma Therapeutics Inc
NASDAQ:CARM
|
US |
|
Antisense Therapeutics Ltd
ASX:ANP
|
AU |
|
S
|
Samjin Pharmaceutical Co Ltd
KRX:005500
|
KR |
|
E
|
Elcom Technology Communications Corp
VN:ELC
|
VN |
|
Power REIT
F:P8P
|
US |
|
Kasen International Holdings Ltd
HKEX:496
|
CN |
Wall Street
Price Targets
APOTEA Price Targets Summary
Apotea AB (publ)
According to Wall Street analysts, the average 1-year price target for APOTEA is 84.15 SEK with a low forecast of 70.7 SEK and a high forecast of 99.75 SEK.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is APOTEA's stock price target?
Price Target
84.15
SEK
According to Wall Street analysts, the average 1-year price target for APOTEA is 84.15 SEK with a low forecast of 70.7 SEK and a high forecast of 99.75 SEK.
What is Apotea AB (publ)'s Revenue forecast?
Projected CAGR
12%
For the last 3 years the compound annual growth rate for Apotea AB (publ)'s revenue is 14%. The projected CAGR for the next 3 years is 12%.
What is Apotea AB (publ)'s Operating Income forecast?
Projected CAGR
22%
For the last 3 years the compound annual growth rate for Apotea AB (publ)'s operating income is 83%. The projected CAGR for the next 3 years is 22%.
What is Apotea AB (publ)'s Net Income forecast?
Projected CAGR
23%
For the last 3 years the compound annual growth rate for Apotea AB (publ)'s net income is 126%. The projected CAGR for the next 3 years is 23%.
